Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Micro-RNA regulation in pluripotent stem cells Schatten, Gerald Southwest Foundation For Biomedical Research
Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome Roth, Bryan University of North Carolina at Chapel Hill
Caspr2 dysfunction in autism spectrum disorders Robbins, Elissa Yale University
A novel cell-based assay for autism research and drug discovery Restifo, Linda University of Arizona
Role of a novel Wnt pathway in autism spectrum disorders Reichardt, Louis University of California, San Francisco
Genetic models of serotonin transporter regulation linked to mental disorders Ramamoorthy, Sammanda Medical University of South Carolina
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Neuroligin function in vivo: Implications for autism and mental retardation Powell, Craig University of Texas Southwestern Medical Center
Animal models of autism: Pathogenesis and treatment Powell, Craig University of Texas Southwestern Medical Center
High-resolution diffusion tensor imaging in mouse models relevant to autism Poptani, Harish University of Pennsylvania
Neurogenetic model of social behavior heterogeneity in autism spectrum disorders Platt, Michael Duke University
Small-molecule compounds for treating autism spectrum disorders Philpot, Ben The University of North Carolina at Chapel Hill
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Pedersen, Cort University of North Carolina at Chapel Hill
Novel probiotic therapies for autism Patterson, Paul California Institute of Technology
Role of L-type calcium channels in hippocampal neuronal network activity Owen, Scott Stanford University
Systematic analysis of neural circuitry in mouse models of autism Osten, Pavel Cold Spring Harbor Laboratory
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2 Nakanishi, Nobuki Burnham Institute
Characterization of a novel mouse model of restricted repetitive behaviors Moy, Sheryl University of North Carolina at Chapel Hill
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Moy, Sheryl University of North Carolina at Chapel Hill
16p11.2: defining the gene(s) responsible Mills, Alea Cold Spring Harbor Laboratory
Novel models to define the genetic basis of autism Mills, Alea Cold Spring Harbor Laboratory
A mouse knock-in model for ENGRAILED 2 autism susceptibility Millonig, James University of Medicine & Dentistry of New Jersey
Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila McDonald, Thomas Albert Einstein College of Medicine of Yeshiva University
Synaptic deficits of iPS cell-derived neurons from patients with autism Mao, Rong Stanford University
NrCAM, a candidate susceptibility gene for visual processing deficits in autism Maness, Patricia University of North Carolina at Chapel Hill